Jyothi Manohar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jyothi Manohar has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Maria Laura Martin
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
38 shared publications - Jenna E. Moyer
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, USA
37 shared publications - Hui-Hsuan Kuo
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
21 shared publications - Juan Miguel Mosquera
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
21 shared publications - Melissa K. Frey
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY
21 shared publications - Michael Sigouros
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
21 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eadz3351
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities
We developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5′-diphosphate–ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53 -mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eadz3351
Open AccessPatient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities
We developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5′-diphosphate–ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53 -mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of inhibitors tested in HTDS alone or in combination with gefitinib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of inhibitors tested in HTDS alone or in combination with gefitinib.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
PDTO breast media composition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
PDTO breast media composition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S3 contains all statistically significant DEGs from RNAseq data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S3 contains all statistically significant DEGs from RNAseq data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of primers and vectors used in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of primers and vectors used in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
IC50 values (µM) obtained for tested inhibitors in breast PDTO lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
IC50 values (µM) obtained for tested inhibitors in breast PDTO lines.